Adial Pharmaceuticals Inc Overview
Industry: Biotechnology
Sector: Healthcare
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia. Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcoho Read MoreAdial Pharmaceuticals Inc is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.
Adial Pharmaceuticals Inc
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Net loss was -$2M (from $2.2M). Cash was $4.6M.
What changed
- Net loss was -$2M (from $2.2M).
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
Recent News
Earnings Per Share
Return on Equity
ROE
Company 0%
Sector Median 0%
ROE
Company 0%
Sector Median 0%
ROE
Company 0%
Sector Median 0%
ROE
Company 0%
Sector Median 0%
Metric chart temporarily unavailable.
Net Margin
Net Margin
Company 0%
Sector Median 0%
Net Margin
Company 0%
Sector Median 0%
Net Margin
Company 0%
Sector Median 0%
Net Margin
Company 0%
Sector Median 0%
Metric chart temporarily unavailable.
Leverage
Leverage
Company 0
Sector Median 0
Leverage
Company 0
Sector Median 0
Leverage
Company 0
Sector Median 0
Leverage
Company 0
Sector Median 0
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.